The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities (Q48000346)

7 February 2018

title

The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities (English)

1 reference

7 February 2018

1 reference

Wafik Zaky

1

1 reference

7 February 2018

Christa Manton

2

1 reference

7 February 2018

Claudia P Miller

3

1 reference

7 February 2018

Soumen Khatua

4

1 reference

7 February 2018

Vidya Gopalakrishnan

5

1 reference

7 February 2018

Joya Chandra

6

1 reference

7 February 2018

publication date

25 October 2017

1 reference

7 February 2018

Cancer and Metastasis Reviews

published in

1 reference

7 February 2018

volume

36

1 reference

7 February 2018

issue

4

1 reference

7 February 2018

page(s)

617-633

1 reference

7 February 2018

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

1 reference

Origin and function of ubiquitin-like proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Building ubiquitin chains: E2 enzymes at work

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Structural basis for the activation of 20S proteasomes by 11S regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Myc proteins in brain tumor development and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Tyrosine kinase expression in pediatric high grade astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Role of platelet-derived growth factors in physiology and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A human brain tumor-derived PDGFR-alpha deletion mutant is transforming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Genetic pathways to primary and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Treatment of high-grade glioma in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

21 January 2018

Modes of p53 regulation

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Mdm2 and MdmX partner to regulate p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A mouse model of the most aggressive subgroup of human medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

An animal model of MYC-driven medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

APC/CCdc20targets E2F1 for degradation in prometaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Novel functions for the anaphase-promoting complex in neurobiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The ubiquitin-proteasome system in glioma cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Inflammation meets cancer, with NF-κB as the matchmaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Introduction to NF-kappaB: players, pathways, perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Deubiquitinases in the regulation of NF-κB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

NFKBIA deletion in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Pediatric medulloblastoma - update on molecular classification driving targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Subtypes of medulloblastoma have distinct developmental origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

APC mutations in sporadic medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The ubiquitin proteasome system in neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Convergence of Wnt, beta-catenin, and cadherin pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Mechanisms of Wnt signaling in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Beta-catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Medulloblastoma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Suppressor of fused controls mid-hindbrain patterning and cerebellar morphogenesis via GLI3 repressor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Hedgehog/Gli control by ubiquitination/acetylation interplay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Shh signaling protects Atoh1 from degradation mediated by the E3 ubiquitin ligase Huwe1 in neural precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Roles of F-box proteins in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Oncoprotein stabilization in brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Nuclear factor-kappaB in development, prevention, and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

NF-kappaB and cancer: how intimate is this relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Molecular subgroups of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

The complexity of NF-κB signaling in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Prevention of experimental colitis by a selective inhibitor of the immunoproteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Functional evaluation of therapeutic response for a mouse model of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Structure and function of the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Quantification and pharmacokinetics of blood-brain barrier disruption in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Proteasome Activation by Small Molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-017-9700-2

10.1007/S10555-017-9700-2

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

release_ig5evqdfpvfcnbvvnuv5cn3ypq

Fatcat ID

0 references

1 reference

7 February 2018